Do analysts prefer ICLR or IQV?

Icon currently has a consensus target price of $170.40, indicating a potential upside of 0.64%. IQVIA has a consensus target price of $243.63, indicating a potential downside of 7.05%. Given Icon's higher probable upside, analysts clearly believe Icon is more favorable than IQVIA. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Icon 2 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.41 IQVIA 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has preferable earnings & valuation, ICLR or IQV?

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Icon $8.29B 1.56 $229.34M $4.26 39.74 IQVIA $16.98B 2.54 $1.36B $8.06 32.52

Is ICLR or IQV more profitable?

IQVIA has a net margin of 8.10% compared to Icon's net margin of 3.99%. IQVIA's return on equity of 30.25% beat Icon's return on equity. Company Net Margins Return on Equity Return on Assets Icon 3.99% 8.02% 4.56% IQVIA 8.10% 30.25% 6.54%

Does the media prefer ICLR or IQV?

In the previous week, IQVIA had 18 more articles in the media than Icon. MarketBeat recorded 22 mentions for IQVIA and 4 mentions for Icon. Icon's average media sentiment score of 1.76 beat IQVIA's score of 1.01 indicating that Icon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Icon 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive IQVIA 14 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, IQV or MEDP?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.98B 2.54 $1.36B $8.06 32.52 Medpace $2.53B 6.48 $451.12M $17.06 34.44

Is IQV or MEDP more profitable?

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.10% 30.25% 6.54% Medpace 17.67% 110.15% 24.84%

Does the media refer more to IQV or MEDP?

In the previous week, IQVIA had 13 more articles in the media than Medpace. MarketBeat recorded 22 mentions for IQVIA and 9 mentions for Medpace. Medpace's average media sentiment score of 1.47 beat IQVIA's score of 1.01 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 14 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, IQV or TECH?

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.98B 2.54 $1.36B $8.06 32.52 Bio-Techne $1.22B 9.31 $181.86M $1.15 62.71

Is IQV or TECH more profitable?

Bio-Techne has a net margin of 14.97% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Bio-Techne's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.10% 30.25% 6.54% Bio-Techne 14.97% 13.23% 10.61%

Does the media favor IQV or TECH?

In the previous week, IQVIA had 13 more articles in the media than Bio-Techne. MarketBeat recorded 22 mentions for IQVIA and 9 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.26 beat IQVIA's score of 1.01 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 14 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IQV or A?

In the previous week, IQVIA had 3 more articles in the media than Agilent Technologies. MarketBeat recorded 22 mentions for IQVIA and 19 mentions for Agilent Technologies. IQVIA's average media sentiment score of 1.01 beat Agilent Technologies' score of 0.68 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 14 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilent Technologies 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IQVIA (IQV) Competitors

$262.09 +4.79 (+1.86%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$263.80 +1.71 (+0.65%)

As of 09/11/2026 07:30 PM Eastern

Compare

IQV vs. ICLR, MEDP, TECH, A, and CRL

Should you buy IQVIA stock or one of its competitors? IQVIA's main competitors and comparable companies include Icon (ICLR), Medpace (MEDP), Bio-Techne (TECH), Agilent Technologies (A), and Charles River Laboratories International (CRL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does IQVIA compare to Icon?

Icon (NASDAQ:ICLR) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

95.6% of Icon shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 44.0% of Icon shares are owned by insiders. Comparatively, 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.29B	1.56	$229.34M	$4.26	39.74
IQVIA	$16.98B	2.54	$1.36B	$8.06	32.52

Icon currently has a consensus target price of $170.40, indicating a potential upside of 0.64%. IQVIA has a consensus target price of $243.63, indicating a potential downside of 7.05%. Given Icon's higher probable upside, analysts clearly believe Icon is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, IQVIA had 18 more articles in the media than Icon. MarketBeat recorded 22 mentions for IQVIA and 4 mentions for Icon. Icon's average media sentiment score of 1.76 beat IQVIA's score of 1.01 indicating that Icon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
IQVIA	14 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Icon has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

IQVIA has a net margin of 8.10% compared to Icon's net margin of 3.99%. IQVIA's return on equity of 30.25% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
IQVIA	8.10%	30.25%	6.54%

Summary

IQVIA beats Icon on 10 of the 16 factors compared between the two stocks.

How does IQVIA compare to Medpace?

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.98B	2.54	$1.36B	$8.06	32.52
Medpace	$2.53B	6.48	$451.12M	$17.06	34.44

IQVIA currently has a consensus target price of $243.63, indicating a potential downside of 7.05%. Medpace has a consensus target price of $595.20, indicating a potential upside of 1.31%. Given Medpace's higher possible upside, analysts plainly believe Medpace is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

IQVIA has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

In the previous week, IQVIA had 13 more articles in the media than Medpace. MarketBeat recorded 22 mentions for IQVIA and 9 mentions for Medpace. Medpace's average media sentiment score of 1.47 beat IQVIA's score of 1.01 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	14 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.7% of IQVIA shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Medpace	17.67%	110.15%	24.84%

Summary

Medpace beats IQVIA on 9 of the 17 factors compared between the two stocks.

How does IQVIA compare to Bio-Techne?

IQVIA (NYSE:IQV) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

IQVIA currently has a consensus price target of $243.63, indicating a potential downside of 7.05%. Bio-Techne has a consensus price target of $68.92, indicating a potential downside of 4.43%. Given Bio-Techne's higher probable upside, analysts plainly believe Bio-Techne is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.98B	2.54	$1.36B	$8.06	32.52
Bio-Techne	$1.22B	9.31	$181.86M	$1.15	62.71

89.6% of IQVIA shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 1.7% of IQVIA shares are held by insiders. Comparatively, 1.3% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, IQVIA had 13 more articles in the media than Bio-Techne. MarketBeat recorded 22 mentions for IQVIA and 9 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.26 beat IQVIA's score of 1.01 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	14 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne has a net margin of 14.97% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Bio-Techne	14.97%	13.23%	10.61%

Summary

IQVIA beats Bio-Techne on 9 of the 17 factors compared between the two stocks.

How does IQVIA compare to Agilent Technologies?

IQVIA (NYSE:IQV) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

IQVIA has higher revenue and earnings than Agilent Technologies. Agilent Technologies is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.98B	2.54	$1.36B	$8.06	32.52
Agilent Technologies	$7.37B	5.62	$1.30B	$5.08	28.92

IQVIA presently has a consensus target price of $243.63, indicating a potential downside of 7.05%. Agilent Technologies has a consensus target price of $170.33, indicating a potential upside of 15.95%. Given Agilent Technologies' higher probable upside, analysts clearly believe Agilent Technologies is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Agilent Technologies	0 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, IQVIA had 3 more articles in the media than Agilent Technologies. MarketBeat recorded 22 mentions for IQVIA and 19 mentions for Agilent Technologies. IQVIA's average media sentiment score of 1.01 beat Agilent Technologies' score of 0.68 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	14 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

89.6% of IQVIA shares are held by institutional investors. Comparatively, 87.4% of Agilent Technologies shares are held by institutional investors. 1.7% of IQVIA shares are held by insiders. Comparatively, 0.2% of Agilent Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Agilent Technologies has a net margin of 19.53% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Agilent Technologies	19.53%	24.45%	13.09%

Summary

IQVIA beats Agilent Technologies on 10 of the 16 factors compared between the two stocks.

How does IQVIA compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IQVIA has a net margin of 8.10% compared to Charles River Laboratories International's net margin of -5.96%. IQVIA's return on equity of 30.25% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
IQVIA	8.10%	30.25%	6.54%

Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Charles River Laboratories International presently has a consensus price target of $265.69, indicating a potential downside of 4.44%. IQVIA has a consensus price target of $243.63, indicating a potential downside of 7.05%. Given Charles River Laboratories International's higher possible upside, research analysts plainly believe Charles River Laboratories International is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.00B	3.32	-$144.34M	-$4.85	N/A
IQVIA	$16.98B	2.54	$1.36B	$8.06	32.52

In the previous week, IQVIA had 18 more articles in the media than Charles River Laboratories International. MarketBeat recorded 22 mentions for IQVIA and 4 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.28 beat IQVIA's score of 1.01 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	14 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IQVIA beats Charles River Laboratories International on 12 of the 17 factors compared between the two stocks.

Get IQVIA News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IQV vs. The Competition

Export

Metric	IQVIA	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$42.35B	$9.69B	$7.16B	$23.20B
Dividend Yield	N/A	1.47%	2.56%	3.56%
P/E Ratio	32.52	66.42	272.98	28.69
Price / Sales	2.54	287.71	654.99	102.56
Price / Cash	14.40	26.25	77.04	33.82
Price / Book	6.73	5.28	10.33	4.74
Net Income	$1.36B	$56.67B	$3.49B	$1.07B
7 Day Performance	-1.96%	-2.08%	-3.33%	-1.99%
1 Month Performance	8.41%	-1.60%	-0.42%	-2.68%
1 Year Performance	39.90%	25.11%	19.22%	10.45%

IQVIA Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IQV IQVIA	3.6939 of 5 stars	$262.09 +1.9%	$243.63 -7.0%	+37.6%	$42.35B	$16.98B	32.52	93,000	Positive News Analyst Upgrade
ICLR Icon	2.499 of 5 stars	$164.85 flat	$170.40 +3.4%	-3.3%	$12.62B	$8.25B	38.70	40,100	Positive News
MEDP Medpace	2.5908 of 5 stars	$591.29 flat	$595.20 +0.7%	+18.1%	$16.50B	$2.53B	34.66	6,200	Positive News
TECH Bio-Techne	3.495 of 5 stars	$72.43 flat	$68.92 -4.8%	+35.5%	$11.36B	$1.22B	62.98	3,000	Positive News
A Agilent Technologies	4.4604 of 5 stars	$150.60 -0.2%	$170.33 +13.1%	+15.8%	$42.53B	$6.95B	29.65	18,100	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:IQV) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Competitors